2026-04-17T03:12:35Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/71682025-10-24T10:29:56Zcom_2072_378070com_2072_378040col_2072_378092

COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee Turner, Paul El-Gamal, Yehia Ebisawa, Motohiro Ansotegui Zubeldia, Ignacio Javier Campbell, Dianne Cardona, Victoria COVID-19 (Malaltia) - Vacunació Anafilaxi Medicaments - Efectes secundaris CHEMICALS AND DRUGS::Complex Mixtures::Biological Products::Vaccines::Viral Vaccines Other subheadings::Other subheadings::Other subheadings::/adverse effects DISEASES::Immune System Diseases::Hypersensitivity::Hypersensitivity, Immediate::Anaphylaxis DISEASES::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections COMPUESTOS QUÍMICOS Y DROGAS::mezclas complejas::productos biológicos::vacunas::vacunas víricas Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos ENFERMEDADES::enfermedades del sistema inmune::hipersensibilidad::hipersensibilidad inmediata::anafilaxia ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus Anafilaxi; COVID-19; Polietilenglicol Anafilaxia; COVID-19; Polietilenglicol Anaphylaxis; COVID-19; Polyethylene glycol Vaccines against COVID-19 (and its emerging variants) are an essential global intervention to control the current pandemic situation. Vaccines often cause adverse events; however, the vast majority of adverse events following immunization (AEFI) are a consequence of the vaccine stimulating a protective immune response, and not allergic in etiology. Anaphylaxis as an AEFI is uncommon, occurring at a rate of less than 1 per million doses for most vaccines. However, within the first days of initiating mass vaccination with the Pfizer-BioNTech COVID-19 vaccine BNT162b2, there were reports of anaphylaxis from the United Kingdom and United States. More recent data imply an incidence of anaphylaxis closer to 1:200,000 doses with respect to the Pfizer-BioNTech vaccine. In this position paper, we discuss the background to reactions to the current COVID-19 vaccines and relevant steps to mitigate against the risk of anaphylaxis as an AEFI. We propose a global surveillance strategy led by allergists in order to understand the potential risk and generate data to inform evidence-based guidance, and thus provide reassurance to public health bodies and members of the public. 2025-10-24T10:29:56Z 2025-10-24T10:29:56Z 2025-10-24T10:29:56Z 2022-03-14T13:23:13Z 2022-03-14T13:23:13Z 2021-02 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://hdl.handle.net/11351/7168 World Allergy Organization Journal;14(2) https://doi.org/10.1016/j.waojou.2021.100517 Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess Elsevier Scientia